Author + information
- Received February 12, 2020
- Revision received April 13, 2020
- Accepted April 13, 2020
- Published online July 27, 2020.
- Mohammed M. Chowdhury, MB ChB, PhDa,d,∗,
- Kanwarpal Singh, PhDb,∗,
- Mazen S. Albaghdadi, MD, MSca,
- Haitham Khraishah, MDa,e,
- Adam Mauskapf, BSa,
- Chase W. Kessinger, PhDa,
- Eric A. Osborn, MD, PhDa,e,
- Stephan Kellnberger, PhDa,
- Zhonglie Piao, PhDb,
- Christian L. Lino Cardenas, PharmD, PhDa,
- Madeleine S. Grau, BAa,
- Michael R. Jaff, DOf,
- Kenneth Rosenfield, MDa,
- Peter Libby, MDg,
- Elazer R. Edelman, MD, PhDg,h,
- Mark E. Lindsay, MD, PhDa,
- Guillermo J. Tearney, MD, PhDb,c,†∗ ( and )
- Farouc A. Jaffer, MD, PhDa,b,†∗ ()
- aCardiovascular Research Center, Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
- bWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
- cDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
- dDepartment of Vascular and Endovascular Surgery, Department of Surgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom
- eCardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- fDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
- gCardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
- hInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts
- ↵∗Address for Correspondence:
Dr. Farouc Jaffer or Dr. Gary Tearney, Massachusetts General Hospital, Cardiovascular Research Center, Simches Research Building, Room 3206, Boston, Massachusetts 02114.
• Restenosis limits the efficacy of PTA or stent treatment of atherosclerosis in peripheral and coronary artery disease.
• Paclitaxel DCBs effectively reduce restenosis; however, recently, their overall safety profile has been called into question.
• In an in vivo molecular-structural imaging study of 25 rabbits with experimental atherosclerosis, DCB-PTA, plain PTA, or sham-PTA was investigated using serial intravascular NIRF-OCT and IVUS.
• DCB-PTA reduced lesion inflammation on NIRF-OCT and halted lesion progression on IVUS, compared with PTA or sham-PTA.
• These findings indicated the potential for DCBs to serve effectively and safely as a regional anti-atherosclerosis therapy.
Paclitaxel drug-coated balloons (DCBs) reduce restenosis, but their overall safety has recently raised concerns. This study hypothesized that DCBs could lessen inflammation and reduce plaque progression. Using 25 rabbits with cholesterol feeding- and balloon injury-induced lesions, DCB-percutaneous transluminal angioplasty (PTA), plain PTA, or sham-PTA (balloon insertion without inflation) was investigated using serial intravascular near-infrared fluorescence−optical coherence tomography and serial intravascular ultrasound. In these experiments, DCB-PTA reduced inflammation and plaque burden in nonobstructive lesions compared with PTA or sham-PTA. These findings indicated the potential for DCBs to serve safely as regional anti-atherosclerosis therapy.
↵∗ Drs. Chowdhury and Singh contributed equally to this work and are joint first authors.
↵† Drs. Tearney and Jaffer contributed equally to this work and are joint senior authors. Juan Granada, MD, served as Guest Editor for this paper.
Dr. Chowdhury is supported by fellowships from the Royal College of Surgeons of England, the British Heart Foundation (BHF; FS/16/29/31957), the University of Cambridge (Parke-Davies Fellowship Award), and the President’s Early Career Award from the Circulation Foundation (UK Vascular Charity– awarded to Mr P. Coughlin, Vascular Surgery Department, University of Cambridge). Dr. Jaffer is supported by the National Institutes of Health (NIH) (grants R01 HL122388, R01 HL137913, R01 HL150538) and an MGH Hassenfeld Research Scholar Award. Dr. Osborn is supported by the NIH (grant K08 HL130465). Dr. Kellnberger is supported by an American Heart Association (AHA) postdoctoral fellowship award (17POST33670288). Drs. Cardenas and Lindsay are supported by the Toomey Fund for Aortic Dissection and the Fredman Fellowship. Dr. Libby is supported by the National Heart, Lung, and Blood Institute (R01HL080472), AHA (18CSA34080399), and RRM Charitable Fund. Dr. Edelman was supported in part by a grant from the NIH (R01GM49039). Dr. Albaghdadi has taken part in sponsored research from Kowa, Pfizer, and Sanofi. Dr. Olsen has been a consultant for Abbott Vascular; and has been a member of the scientific advisory board for Dyad Medical. Dr. Jaff has been a noncompensated advisor to Boston Scientific; has been a compensated advisor to Medtronic Vascular, Philips/Volcano, Biotronik, Vactronix, EFemoral, and R3 Vascular; and has been an equity shareholder in Vascular Therapies, EFemoral, and R3 Vascular. Dr. Rosenfield has been a member of the scientific advisory board and a consultant for Abbott Vascular, Access Vascular, Boston Scientific-BTG, Volcano-Philips, Surmodics, Cruzar, Magneto, Micell, Summa Therapeutics, and Thrombolex; holds stocks/stock options in Access Vascular, Accolade, Contego, Endospan, Embolitech, Eximo, JanaCare, PQ Bypass, Primacea, MD Insider, Shockwave, Silk Road, Summa Therapeutics, Cruzar Systems, Capture Vascular, and Magneto; and has been a Board Member for Viva Physicians and National PERT Consortium. Dr. Libby has received research funding in the last 2 years from Novartis; has been an unpaid consultant to, or involved in clinical trials for, Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Pfizer, Sanofi-Regeneron, and XBiotiech, Inc; and has been a member of scientific advisory board for Amgen, Athera Biotechnologies, Cordivia Therapeutics, DalCor Pharmaceuticals, IFM Therapeutics, Kowa Pharmaceuticals, Olatec Therapuetics, Medimmune, Novartis, and XBiotech, Inc. Dr. Tearney has taken part in sponsored research from VivoLight, Canon, and AstraZeneca; has received royalties and catheter components from Terumo; and has a financial/fiduciary interest and consults for SpectraWAVE, a company developing an OCT-NIRS intracoronary imaging system and catheter. Dr. Jaffer has taken part in sponsored research from Canon and Siemens; has been a consultant for Boston Scientific, Abbott Vascular, Siemens, Biotronik, Philips, and Acrostak; and holds equity interest in Intravascular Imaging, Inc. Drs. Tearney and Jaffer have received royalties for Terumo, Canon, and Spectrawave for a patent pending with Massachusetts General Hospital.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received February 12, 2020.
- Revision received April 13, 2020.
- Accepted April 13, 2020.
- 2020 The Authors